Lyell Immunopharma, Inc. (LYEL) Total Assets by Year
Lyell Immunopharma, Inc. closed fiscal year 2025 with $340.1M in total assets, $91.8M in total liabilities and $248.2M in shareholder equity. This represents a decrease of 30.7% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Lyell Immunopharma, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
LYEL Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K |
|---|---|---|---|---|---|---|---|
| Total Assets | $340.1M-30.7% | $490.9M-34.6% | $750.0M-20.0% | $937.6M-16.8% | $1.1B+24.1% | $908.3M | N/A |
| Total Liabilities | $91.8M-15.0% | $108.0M+13.6% | $95.1M-8.9% | $104.3M-47.2% | $197.6M-83.5% | $1.2B | N/A |
| Total Equity | $248.2M-35.2% | $382.8M-41.5% | $655.0M-21.4% | $833.3M-10.4% | $929.8M+417.8% | -$292.5M-163.3% | -$111.1M |
LYEL Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $311.2M-19.3% | $350.6M-18.4% | $340.1M-30.7% | $408.0M-34.1% | $385.5M-41.1% | $429.8M-38.1% | $490.9M-34.6% | $619.2M-22.1% | $654.1M-21.7% | $694.2M-21.2% | $750.0M-20.0% | $795.0M-18.7% |
| Total Liabilities | $77.3M-10.6% | $77.0M-17.5% | $91.8M-15.0% | $78.8M-10.9% | $86.5M-1.3% | $93.3M+2.4% | $108.0M+13.6% | $88.5M-9.1% | $87.6M-11.0% | $91.1M-5.8% | $95.1M-8.9% | $97.4M-38.0% |
| Total Equity | $233.8M-21.8% | $273.7M-18.7% | $248.2M-35.2% | $329.1M-38.0% | $298.9M-47.2% | $336.5M-44.2% | $382.8M-41.5% | $530.7M-23.9% | $566.5M-23.1% | $603.2M-23.0% | $655.0M-21.4% | $697.6M-14.9% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Lyell Immunopharma, Inc. financials
Frequently Asked Questions
What was Lyell Immunopharma, Inc.'s total assets in fiscal year 2025?
Lyell Immunopharma, Inc. closed fiscal year 2025 with $340.1M in total assets, $91.8M in total liabilities and $248.2M in shareholder equity.
How fast is Lyell Immunopharma, Inc.'s total assets growing?
Lyell Immunopharma, Inc. (LYEL) total assets fell by 30.7% year over year, from $490.9M to $340.1M in fiscal year 2025.
What was Lyell Immunopharma, Inc.'s total assets in the most recent quarter?
Lyell Immunopharma, Inc. (LYEL) reported $311.2M in total assets in Q2 2026. This represents a decrease of 19.3% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Lyell Immunopharma, Inc. (LYEL) reported on that line in every period on record.